| 1A. Paolo Fundarò | | | 1B. Jerome Durso | | | 1C. Srinivas Akkaraju, M.D., Ph.D. | | |||
| 1D. Luca Benatti, Ph.D. | | | 1E. Daniel Bradbury | | | 1F. Keith Gottesdiener, M.D. | | |||
| 1G. Nancy Miller-Rich | | | 1H. Mark Pruzanski, M.D. | | | 1I. Dagmar Rosa-Bjorkeson | | |||
| 1J. Gino Santini | | | 1K. Glenn Sblendorio | | | | |
| | | Page | | |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | 15 | | | |
| | | | 15 | | | |
| | | | 15 | | | |
| | | | 16 | | | |
| | | | 16 | | | |
| | | | 16 | | | |
| | | | 16 | | | |
| | | | 16 | | | |
| | | | 17 | | | |
| | | | 17 | | | |
| | | | 17 | | | |
| | | | 18 | | | |
| | | | 19 | |||
| | ||||||
| | | | | | ||
| | | | 20 | | | |
| | | | 20 | | | |
| | | | 22 | | | |
| | | | ||||
| | ||||||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | ||||
| |
| | | Page | | |||
| | | | 28 | | | |
| | | | 29 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | 62 | | | |
| | | | 63 | | | |
| | | | 65 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | ||||
| | ||||||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | 75 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | ||||
| | ||||||
| | | | | | ||
| | | | | | ||
| | | | | | ||
APPENDIX: AMENDED AND RESTATED EQUITY INCENTIVE PLAN | | | | | | | |
Director | | Age | | Director Since | | | Age | | Director Since | | ||||||||||||||||
Paolo Fundarò(1) | | | | 47 | | | | | 2006 | | | | | | 48 | | | | | 2006 | | | ||||
Jerome Durso | | | | 53 | | | | | 2021 | | | | | | 54 | | | | | 2021 | | | ||||
Srinivas Akkaraju, M.D., Ph.D. | | | | 53 | | | | | 2012 | | | | | | 54 | | | | | 2012 | | | ||||
Luca Benatti, Ph.D. | | | | 60 | | | | | 2014 | | | | | | 61 | | | | | 2014 | | | ||||
Daniel Bradbury | | | | 60 | | | | | 2016 | | | | | | 60 | | | | | 2016 | | | ||||
Keith Gottesdiener, M.D. | | | | 67 | | | | | 2016 | | | | | | 68 | | | | | 2016 | | | ||||
Nancy Miller-Rich(5) | | | | 62 | | | | | 2018 | | | |||||||||||||||
Nancy Miller-Rich(4)(5) | | | | 63 | | | | | 2018 | | | |||||||||||||||
Mark Pruzanski, M.D. | | | | 53 | | | | | 2002 | | | | | | 54 | | | | | 2002 | | | ||||
Dagmar Rosa-Bjorkeson | | | | 57 | | | | | 2021 | | | | | | 58 | | | | | 2021 | | | ||||
Gino Santini | | | | 64 | | | | | 2015 | | | | | | 65 | | | | | 2015 | | | ||||
Glenn Sblendorio | | | | 65 | | | | | 2014 | | | | | | 66 | | | | | 2014 | | |
Per Share Exercise Price ($) | | | Number of Outstanding Options in Range | | | Weighted Average Exercise Price ($) | | | Weighted Average Remaining Term | | | Exchange Ratio | | | New Options Issuable (assuming full participation) | | |||||||||||||||
55.59 – 75.00 | | | | | 235,000 | | | | | | 61.57 | | | | | | 6.72 | | | | | | 1.25 – 1 | | | | | | 188,000 | | |
75.01 – 115.00 | | | | | 576,000 | | | | | | 103.07 | | | | | | 7.46 | | | | | | 1.50 – 1 | | | | | | 384,000 | | |
115.01 – 125.00 | | | | | 60,000 | | | | | | 120.62 | | | | | | 5.26 | | | | | | 2.00 – 1 | | | | | | 30,000 | | |
125+ | | | | | 96,000 | | | | | | 201.20 | | | | | | 3.85 | | | | | | 4.00 – 1 | | | | | | 24,000 | | |
Board Diversity Matrix (As of April 1, 2022) | | ||||||||||||
Total Number of Directors | | | 11 | | |||||||||
| | | Female | | | Male | | | Non-Binary | | | Did Not Disclose Gender | |
Part I: Gender Identity | | | | | | | | | | | | | |
Directors | | | 2 | | | 8 | | | — | | | 1 | |
Part II: Demographic Background | | | | | | | | | | | | | |
African American or Black | | | — | | | — | | | — | | | — | |
Alaskan Native or Native American | | | — | | | — | | | — | | | — | |
Asian | | | — | | | 1 | | | — | | | — | |
Hispanic or Latinx | | | 1 | | | — | | | — | | | — | |
Native Hawaiian or Pacific Islander | | | — | | | — | | | — | | | — | |
White | | | 1 | | | 6 | | | — | | | — | |
Two or More Races or Ethnicities | | | — | | | — | | | — | | | — | |
LGBTQ+ | | | — | | |||||||||
Did Not Disclose Demographic Background | | | 2 | |
Name | | Board | | Audit | | Compensation | | Nominating and Governance | | Research and Development | | | Board | | Audit | | Compensation | | Nominating and Governance | | Research and Development | | ||||||||||
Paolo Fundarò | | C | | – | | – | | – | | – | | | C | | – | | – | | – | | – | | ||||||||||
Jerome Durso | | M | | – | | – | | – | | – | | |||||||||||||||||||||
Srinivas Akkaraju, M.D., Ph.D. | | M | | – | | – | | – | | M | | | M | | – | | – | | – | | M | | ||||||||||
Luca Benatti, Ph.D. | | M | | – | | – | | M | | C | | | M | | – | | – | | C | | M | | ||||||||||
Daniel Bradbury | | M | | M | | – | | M | | – | | | M | | M | | – | | M | | – | | ||||||||||
Keith Gottesdiener, M.D. | | M | | – | | – | | – | | M | | | M | | – | | – | | – | | C | | ||||||||||
Nancy Miller-Rich | | M | | – | | M | | – | | – | | | M | | – | | M | | M | | – | | ||||||||||
Mark Pruzanski, M.D. | | M | | – | | – | | – | | M | | |||||||||||||||||||||
Dagmar Rosa-Bjorkeson | | M | | – | | M | | – | | – | | |||||||||||||||||||||
Gino Santini | | M | | M | | C | | – | | – | | | M | | M | | C | | – | | – | | ||||||||||
Glenn Sblendorio | | M | | C | | – | | – | | – | | | M | | C | | – | | – | | – | | ||||||||||
Daniel Welch | | M | | – | | M | | C | | – | |
Membership | | Chairperson | | Other Members | | | Chairperson | | Other Members | | ||||||||||||||||
Board of Directors | | | $ | 80,000 | | | | $ | 50,000 | | | |||||||||||||||
Board of Directors. | | | $ | 80,000 | | | | $ | 50,000 | | | |||||||||||||||
Audit Committee | | | $ | 20,000 | | | | $ | 10,000 | | | | | $ | 20,000 | | | | $ | 10,000 | | | ||||
Compensation Committee | | | $ | 15,000 | | | | $ | 7,500 | | | | | $ | 15,000 | | | | $ | 7,500 | | | ||||
Nominating and Governance Committee | | | $ | 10,000 | | | | $ | 5,000 | | | | | $ | 10,000 | | | | $ | 5,000 | | | ||||
Research and Development Committee | | | $ | 10,000 | | | | $ | 5,000 | | | | | $ | 10,000 | | | | $ | 5,000 | | |
Name | | Fees Earned or Paid in Cash ($)(1) | | Stock Awards ($)(2) | | Option Awards ($)(2) | | Total ($) | | | Fees Earned or Paid in Cash ($)(2) | | Stock Awards ($)(3) | | Option Awards ($)(3) | | Total ($) | | ||||||||||||||||||||||||||||||||
Paolo Fundarò | | | | 80,000 | | | | | 116,020 | | | | | 132,254 | | | | | 328,274 | | | | | | 80,000 | | | | | 120,055 | | | | | 120,165 | | | | | 320,220 | | | ||||||||
Srinivas Akkaraju, M.D., Ph.D. | | | | 55,000 | | | | | 116,020 | | | | | 132,254 | | | | | 303,274 | | | |||||||||||||||||||||||||||||
Luca Benatti, Ph.D. | | | | 65,000 | | | | | 116,020 | | | | | 132,254 | | | | | 313,274 | | | |||||||||||||||||||||||||||||
Jerome Durso(1) | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||
Srinivas Akkaraju | | | | 55,000 | | | | | 120,055 | | | | | 120,165 | | | | | 295,220 | | | |||||||||||||||||||||||||||||
Luca Benatti | | | | 65,000 | | | | | 120,055 | | | | | 120,165 | | | | | 305,220 | | | |||||||||||||||||||||||||||||
Daniel Bradbury | | | | 65,000 | | | | | 116,020 | | | | | 132,254 | | | | | 313,274 | | | | | | 65,000 | | | | | 120,055 | | | | | 120,165 | | | | | 305,220 | | | ||||||||
Keith Gottesdiener, M.D. | | | | 55,000 | | | | | 116,020 | | | | | 132,254 | | | | | 303,274 | | | |||||||||||||||||||||||||||||
Keith Gottesdiener | | | | 57,972 | | | | | 120,055 | | | | | 120,165 | | | | | 298,192 | | | |||||||||||||||||||||||||||||
Nancy Miller-Rich | | | | 57,500 | | | | | 116,020 | | | | | 132,254 | | | | | 305,774 | | | | | | 60,472 | | | | | 120,055 | | | | | 120,165 | | | | | 300,692 | | | ||||||||
Mark Pruzanski(1) | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||
Dagmar Rosa-Bjorkeson | | | | 41,958 | | | | | 180,074 | | | | | 180,202 | | | | | 402,235 | | | |||||||||||||||||||||||||||||
Gino Santini | | | | 75,000 | | | | | 116,020 | | | | | 132,254 | | | | | 323,274 | | | | | | 75,000 | | | | | 120,055 | | | | | 120,165 | | | | | 315,220 | | | ||||||||
Glenn Sblendorio | | | | 70,000 | | | | | 116,020 | | | | | 132,254 | | | | | 318,274 | | | | | | 70,000 | | | | | 120,055 | | | | | 120,165 | | | | | 310,220 | | | ||||||||
Daniel Welch | | | | 67,500 | | | | | 116,020 | | | | | 132,254 | | | | | 315,774 | | | |||||||||||||||||||||||||||||
Daniel Welch(1) | | | | 27,375 | | | | | — | | | | | — | | | | | 27,375 | | |
Name | | | Shares Subject to Stock Options | | | RSUs | | ||||||
Paolo Fundarò | | | | | 27,616 | | | | | | 7,029 | | |
Srinivas Akkaraju | | | | | 26,615 | | | | | | 7,029 | | |
Luca Benatti | | | | | 25,912 | | | | | | 7,029 | | |
Daniel Bradbury | | | | | 25,209 | | | | | | 7,029 | | |
Keith Gottesdiener | | | | | 25,209 | | | | | | 7,029 | | |
Nancy Miller-Rich | | | | | 24,913 | | | | | | 7,029 | | |
Dagmar Rosa-Bjorkeson | | | | | 17,719 | | | | | | 10,543 | | |
Gino Santini | | | | | 27,111 | | | | | | 7,029 | | |
Glenn Sblendorio | | | | | 25,912 | | | | | | 7,029 | | |
Daniel Welch(1) | | | | | 15,022 | | | | | | — | | |
Name | | | Shares Subject to Stock Options | | | Restricted Stock Units | | ||||||
Paolo Fundarò | | | | | 15,527 | | | | | | 1,595 | | |
Srinivas Akkaraju, M.D., Ph.D. | | | | | 14,526 | | | | | | 1,595 | | |
Luca Benatti, Ph.D. | | | | | 13,823 | | | | | | 1,595 | | |
Daniel Bradbury | | | | | 13,120 | | | | | | 1,595 | | |
Keith Gottesdiener, M.D. | | | | | 13,120 | | | | | | 1,595 | | |
Nancy Miller-Rich | | | | | 12,824 | | | | | | 3,053 | | |
Gino Santini | | | | | 15,022 | | | | | | 1,595 | | |
Glenn Sblendorio | | | | | 13,823 | | | | | | 1,595 | | |
Daniel Welch | | | | | 15,022 | | | | | | 1,595 | | |
| | | Shares Beneficially Owned(11) | | |||||||||
Name and Address | | | Number of Shares | | | Percentage of Common Stock | | ||||||
5% Stockholders: | | | | | | | | | | | | | |
Genextra S.p.A.(1) | | | | | 4,000,000 | | | | | | 12.1% | | |
FMR LLC(2) | | | | | 3,726,914 | | | | | | 11.2% | | |
The Vanguard Group(3) | | | | | 2,828,955 | | | | | | 8.5% | | |
State Street Corporation(4) | | | | | 2,550,750 | | | | | | 7.7% | | |
BlackRock, Inc.(5) | | | | | 2,498,408 | | | | | | 7.5% | | |
First Trust Portfolios L.P.(6) | | | | | 1,975,601 | | | | | | 6.0% | | |
Directors and Executive Officers: | | | | | | | | | | | | | |
Paolo Fundarò(1) | | | | | 4,036,555 | | | | | | 12.2% | | |
Jerome Durso | | | | | 73,967 | | | | | | * | | |
Srinivas Akkaraju, M.D., Ph.D.(7) | | | | | 678,335 | | | | | | 2.0% | | |
Luca Benatti, Ph.D. | | | | | 24,544 | | | | | | * | | |
Daniel Bradbury(8) | | | | | 29,714 | | | | | | * | | |
Keith Gottesdiener, M.D. | | | | | 23,073 | | | | | | * | | |
Nancy Miller-Rich | | | | | 20,362 | | | | | | * | | |
Mark Pruzanski, M.D.(9) | | | | | 856,763 | | | | | | 2.6% | | |
Dagmar Rosa-Bjorkeson | | | | | — | | | | | | — | | |
Gino Santini | | | | | 23,901 | | | | | | * | | |
Glenn Sblendorio | | | | | 22,504 | | | | | | * | | |
Daniel Welch | | | | | 23,082 | | | | | | * | | |
Sandip Kapadia(10) | | | | | 85,458 | | | | | | * | | |
Richard Kim(10) | | | | | 48,563 | | | | | | * | | |
Lisa Bright(10) | | | | | 79,919 | | | | | | * | | |
Ryan Sullivan(10) | | | | | 24,708 | | | | | | * | | |
Christian Weyer, M.D., M.A.S. | | | | | 32,077 | | | | | | * | | |
All current directors and executive officers as a group (20 persons) | | | | | 5,944,358 | | | | | | 17.9% | | |
| | | Shares Beneficially Owned | | |||||||||
Name and Address | | | Number of Shares | | | Percentage of Common Stock | | ||||||
5% Stockholders: | | | | | | | | | | | | | |
Genextra S.p.A.(1) | | | | | 4,000,000 | | | | | | 13.5% | | |
State Street Corporation(2) | | | | | 3,254,266 | | | | | | 11.0% | | |
FMR LLC(3) | | | | | 2,639,433 | | | | | | 8.9% | | |
BlackRock, Inc.(4) | | | | | 2,232,092 | | | | | | 7.5% | | |
The Vanguard Group(5) | | | | | 1,971,759 | | | | | | 6.6% | | |
Directors and Executive Officers:(6) | | | | | | | | | | | | | |
Paolo Fundarò(1) | | | | | 4,055,673 | | | | | | 13.6% | | |
Jerome Durso | | | | | 123,168 | | | | | | * | | |
Srinivas Akkaraju(7) | | | | | 697,453 | | | | | | 2.3% | | |
Luca Benatti | | | | | 43,662 | | | | | | * | | |
Daniel Bradbury(8) | | | | | 48,832 | | | | | | * | | |
Keith Gottesdiener | | | | | 42,191 | | | | | | * | | |
Nancy Miller-Rich | | | | | 39,480 | | | | | | * | | |
Mark Pruzanski | | | | | 897,255 | | | | | | 3.0% | | |
Dagmar Rosa-Bjorkeson | | | | | 9,422 | | | | | | * | | |
Gino Santini | | | | | 43,019 | | | | | | * | | |
Glenn Sblendorio | | | | | 41,622 | | | | | | * | | |
Andrew Saik(9) | | | | | — | | | | | | — | | |
Sandip Kapadia(10) | | | | | 15,589 | | | | | | * | | |
Rocco Venezia | | | | | 18,235 | | | | | | * | | |
Jared Freedberg | | | | | 32,897 | | | | | | * | | |
Michelle Berrey(9) | | | | | — | | | | | | — | | |
Gail Cawkwell | | | | | 54,211 | | | | | | * | | |
All current directors and executive officers as a group (19 persons) | | | | | 6,244,785 | | | | | | 21.0% | | |
| Mr. Fundarò (34,645 shares), | | | Mr. Durso (89,695 shares), | | | Dr. Akkaraju (33,644 shares), | |
| Dr. Benatti (32,941 shares), | | | Mr. Bradbury (32,238 shares), | | | Dr. Gottesdiener (32,238 shares), | |
| Ms. Miller-Rich (31,942 shares), | | | Dr. Pruzanski (278,362 shares), | | | Ms. Rosa-Bjorkeson (5,907 shares), | |
| Mr. Santini (34,140 shares), | | | Mr. Sblendorio (32,941 shares), | | | Mr. Saik (zero shares), | |
| Mr. Kapadia (zero shares), | | | Mr. Venezia (10,306 shares), | | | Mr. Freedberg (25,900 shares), | |
| Dr. Berrey (zero shares), | | | Dr. Cawkwell (37,646 shares),and | | | | |
Name | | | Age | | | Position | |
Bryan Ball | | | | | Chief Quality Officer; SVP, Operations | | |
M. Michelle Berrey, M.D., M.P.H | | | 55 | | | President of Research & Development; Chief Medical Officer | |
Gail Cawkwell, M.D., | | | 59 | | | SVP, Medical Affairs, Safety & | |
| |||||||
David Ford | | | | | Chief Human Resources Officer | | |
Jared Freedberg | | | | | General Counsel | | |
Linda Richardson | | | | | | ||
Andrew Saik | | | 52 | | | Chief Financial Officer | |
Rocco Venezia | | | | | Chief Accounting | ||
|
Name | | | Title | |
| | President and Chief Executive Officer | | |
| | Chief | | |
Sandip Kapadia | | | (Former) Chief Financial Officer | |
Rocco Venezia | | | (Interim) Chief Financial Officer and | |
| | General Counsel | | |
| | | ||
Gail Cawkwell, M.D., Ph.D. | | | SVP, Medical Affairs, Safety & Pharmacovigilance | |
| | | | |
| | | | |
| | ✓ Steady Growth in Ocaliva Net Sales. Our Ocaliva net sales have risen from $18.2 million in 2016 to ✓ Management Alignment Behind Value Creation. In | | |
| | Key Business Achievements | | | ||||||||||||
| | ✓ | | | | PBC Business Reported Strongest Year to Date, Achieving Significant Worldwide Ocaliva Net | | | ||||||||
| | ✓ | | | | Reduced Operating Expenses and Improved Financial Results. In | | | ||||||||
| | ✓ | | | | Leveraged Commercial Strengths. We leveraged our commercial strengths, and focused from a sales perspective on specialty product distribution, payor coverage, community education, deep relationships in the liver community, expanded use of virtual communications channels, and other ways to succeed both during and coming out of the COVID-19 pandemic. | | | ||||||||
| | ✓ | | | | Continued Work on NASH Development Program. We | | | ||||||||
| | ✓ | | | | Advanced Study of Bezafibrate in Combination with OCA. We | | | ||||||||
| | ✓ | | | | Further Developed INT-787. We | | | ||||||||
| | ✓ | | | | | | |||||||||
| | ✓ | | | | | | |||||||||
| | ✓ | | | | Continued Development of Our Leadership | | |
| | CEO Compensation Highlights | | | ||||||||||||||||||||||||
| | |||||||||||||||||||||||||||
Mr. Jerome Durso became our Chief Executive Officer | | | ||||||||||||||||||||||||||
| | |||||||||||||||||||||||||||
| |
| | Compensation and Governance Best Practices | | | ||||||||||||
| | What We Do | | | ||||||||||||
| | ✓ | | | | Independent Chairman and Majority Independent Board. Paolo Fundarò serves as our Board’s Chairman, and all of the members of our Board other than our current | | | ||||||||
| | ✓ | | | | Additional Independent Board Leadership and Diversity. Gino Santini serves as our Board’s Lead Independent Director, which we believe enhances our Board governance structure and contributes to the overall effectiveness of our Board. In addition, in April 2018 and April 2021, we appointed Nancy Miller-Rich and Dagmar Rosa-Bjorkeson, respectively, as independent directors to our Board, which increased the gender diversity of our Board. We continue to strive to achieve an appropriate balance of diverse backgrounds on the Board and its committees, including in regard to background, perspective, experience, age, gender, and ethnicities, and in February 2021 we revised our Corporate Governance Guidelines to further enhance our commitment to diversity. | | | ||||||||
| | ✓ | | | | Independent Compensation Committee. Our Compensation Committee, which is composed entirely of independent directors, provides independent oversight of our compensation programs. | | | ||||||||
| | ✓ | | | | Independent Compensation Consultant. Our Compensation Committee uses an independent executive compensation consulting firm that reports directly to the | | | ||||||||
| | ✓ | | | | Annual Compensation Review and Analysis. Our Compensation Committee conducts an annual assessment of executive compensation to ensure that we provide competitive compensation packages to attract, retain, reward, and incentivize our executive management team to achieve success for us and our stockholders. | | | ||||||||
| | ✓ | | | | Multiple Performance Elements. In accordance with our performance-based compensation |
philosophy, our executive compensation program incorporates multiple performance elements, including target-based cash incentive bonuses payable upon the achievement of corporate goals and individual performance, and long-term equity incentive compensation, a substantial portion of which consists of stock options and | | | ||||||||||||||
| | ✓ | | | | Significant Portion of Compensation Is at Risk. Under our executive compensation program, a significant portion of compensation is “at risk” based on our performance, including annual cash incentive bonuses, and long-term incentive compensation in the form of equity awards, to align the interests of our executive officers and stockholders. | | | ||||||||
| | ✓ | | | | Market Benchmarking and Use of Reference Peer Group. Our Compensation Committee, with the assistance of its independent compensation consultant, annually analyzes similar life science companies to identify a relevant group of peer companies for purposes of ensuring the reasonableness and competitiveness of our executive compensation program. | | | ||||||||
| | ✓ | | | | Stock Ownership Requirements. We have adopted minimum stock ownership guidelines for our Board, Chief Executive Officer, and other executive officers, including our named executive officers, which require, within specified periods of time, our non-employee directors to hold Company equity with a value equal to at least 3x their annual cash retainer, and our Chief Executive Officer and other executive officers to hold Company equity with a value equal to at least 3x and 1x, respectively, their annual base salary. | | | ||||||||
| | ✓ | | | | Clawback Policy. We have adopted a clawback policy that permits the Company to recover from any current or former executive officer, including any named executive officer, whose fraud or intentional misconduct contributes to the circumstances requiring the Company to prepare an accounting restatement due to material non-compliance of the Company with any financial reporting requirement under U.S. federal securities laws, up to 100% of any incentive-based compensation received by such officer from the Company during the one-year period preceding the date on which the Company is required to prepare such accounting restatement. | | |
| | ✓ | | | | Corporate Governance Guidelines. In 2019, we adopted corporate governance guidelines reflecting our Board’s commitment to building long-term stockholder value with an emphasis on corporate governance. The Nominating and Governance Committee periodically reviews the adequacy and effectiveness of our corporate governance guidelines and recommends any proposed changes to the Board for approval. | | |
| | What We Don’t Do | | | ||||||||||||
| | ✘ | | | | No excise tax gross-ups. We have not provided, or committed to provide, excise tax gross-ups to any of our named executive officers. | | | ||||||||
| | ✘ | | | | No change in control “windfalls”. The change in control protections for our named executive officers are limited to “double-trigger” arrangements, which require both a change in control and a qualifying termination of employment, or in the case of | | | ||||||||
| | ✘ | | | | Limited perquisites. Our named executive officers generally receive the same benefits as are available to all of our salaried employees, with limited recurring exceptions primarily consisting of fully-paid health insurance premiums. | | | ||||||||
| | ✘ | | | | No automatic or guaranteed annual salary increases. We do not provide for any formulaic or guaranteed base salary increases for our named executive officers. | | | ||||||||
| | ✘ | | | | No guaranteed bonuses or annual equity grants. We do not provide guaranteed bonuses or annual equity grants to our named executive officers. | | | ||||||||
| | ✘ | | | | No hedging or pledging of Company stock. Our named executive officers and other employees are restricted from engaging in speculative trading activities, including hedging or pledging | | |
| Key areas of stockholder focus | | | | Our responses | |
| Investors asked about the treatment of outstanding PSUs in the Retirement and Consulting Agreement of our retired CEO Mark Pruzanski. These PSUs vested at the maximum level (150%), although based on our stock performance the PSUs of other NEOs vested last year at 0%. | | | | Regarding Dr. Pruzanski’s retirement, we responded to stockholder concerns by noting that Dr. Pruzanski, as the founder and CEO of the Company, had a long-standing employment agreement, and that the intention of the Retirement and Consulting Agreement was to honor the terms of the employment agreement, particularly regarding equity vesting upon separation. Our management noted that we had reviewed all of our remaining employment agreements with executive officers, and none had provisions for equity vesting similar to those contained in the Retirement and Consulting Agreement. Accordingly, in the judgment of the Compensation Committee, the terms of the Retirement and Consulting Agreement are distinct from the management and evaluation of our go-forward executive compensation program. | |
| During the course of our investor outreach, we explained the challenges of delivering competitive executive compensation, particularly with regards to long-term incentives, in a period where our stock price has been depressed for a sustained period of time. These challenges impact both the attraction of new executive talent, and also the retention and incentivization of existing executives. We shared that, in response to these challenges, the Company has had to deploy new and innovative compensation tools in 2021 and 2022 to respond to these circumstances—and that these tools have proven to be, largely, effective. Investors clearly understood the challenges facing the Company and the competitive pressures driving the needs for innovation in compensation, and requested an explanation of compensation measures implemented, including their usage and effectiveness. | | | | In relation to this request, this Compensation Discussion and Analysis (“CD&A”) contains detailed explanations of the new hire awards issued to attract new executives, the cash retention plans used, selectively, to retain critical talents during 2021, and a new, cash-based, long-term incentive plan aimed at ensuring the competitiveness of the Company’s overall long-term incentive offering for executives. | |
| Investors whom we spoke with were highly complimentary of our executive compensation disclosures, particularly the CD&A portions of our recent proxy statements with respect to comprehensiveness, transparency, and clear explanations of our corporate goals for purposes of payout under our annual cash incentive bonus program. Investors encouraged us to continue these disclosure practices, and improve them further where possible. | | | | In this proxy statement, as in prior years, we continue to seek to provide useful disclosures to investors, including the calculations used to establish payout levels for our 2021 cash bonuses. | |
| | | | | | |||
| | | | | | |||
| | | | | Insmed | | ||
| Radius Health | | | Portola Pharmaceuticals (as of 05/01/20) | | | Omeros | |
| United Therapeutics | | | Supernus Pharmaceuticals | | | PTC Therapeutics | |
| | | | | | | Ultragenyx Pharmaceuticals | |
| Akebia Therapeutics, Inc. | | |||||||||
| Amarin Corporation | | | bluebird bio, Inc. | | ||||||
| | | | | | ||||||
| FibroGen, Inc. | | | | | | |||||
| Ligand Pharmaceuticals Incorporated | | | MidMedx Group, Inc. | | | Omeros Corporation | | |||
| | | PTC Therapeutics Inc. | | | Puma Biotechnology, Inc. | | ||||
| Radius Health, Inc. | | | Supernus Pharmaceuticals, Inc. | | | Vanda Pharmaceuticals Inc. | |
Named Executive Officer | | | 2020 Salary(1) | | | 2019 Salary | | | Change from 2019 | | |||||||||
Mark Pruzanski, M.D. | | | | $ | 759,992 | | | | | $ | 734,292 | | | | | | 3.50% | | |
Jerome Durso | | | | $ | 601,913 | | | | | $ | 573,250 | | | | | | 5.00% | | |
Sandip Kapadia | | | | $ | 478,023 | | | | | $ | 464,100 | | | | | | 3.00% | | |
Richard Kim | | | | $ | 457,294 | | | | | $ | 442,900 | | | | | | 3.25% | | |
Lisa Bright(2) | | | | $ | 481,910 | | | | | $ | 465,613 | | | | | | 3.50% | | |
Ryan Sullivan | | | | $ | 461,113 | | | | | $ | 445,520 | | | | | | 3.50% | | |
Christian Weyer, M.D., M.A.S. | | | | $ | 488,011 | | | | | $ | 472,650 | | | | | | 3.25% | | |
Name | | | 2022 ($) | | | 2021 ($) | | | 2020 ($) | | | Change 2021 to 2022 (%) | | | Change 2020 to 2021 (%) | | |||||||||||||||
Jerome Durso | | | | | 717,000 | | | | | | 690,750 | | | | | | 601,913 | | | | | | 3.80% | | | | | | 14.76% | | |
Andrew Saik | | | | | 493,000 | | | | | | 475,000 | | | | | | — | | | | | | 3.79% | | | | | | N/A | | |
Sandip Kapadia | | | | | — | | | | | | 497,140 | | | | | | 478,023 | | | | | | N/A | | | | | | 4.00% | | |
Rocco Venezia | | | | | 381,500 | | | | | | 318,010 | | | | | | 308,000 | | | | | | 19.96% | | | | | | 3.25% | | |
Jared Freedberg | | | | | 479,000 | | | | | | 461,600 | | | | | | — | | | | | | 3.77% | | | | | | N/A | | |
Michelle Berrey | | | | | 622,500 | | | | | | 600,000 | | | | | | — | | | | | | 3.75% | | | | | | N/A | | |
Gail Cawkwell | | | | | 498,000 | | | | | | 479,950 | | | | | | 461,492 | | | | | | 3.76% | | | | | | 4.00% | | |
2020 Corporate Goal Summary | | | Relative Weighting | | | Assessed Achievement | |
NASH Program | | | 50% | | | 15% | |
Includes specified activities and milestones related to: | | | | ||||
• securing FDA approval for OCA in NASH • executing the launch of OCA in NASH in accordance with the Company’s launch preparation plans • ensuring that launch plans are in place, including with respect to targeting, organizational capabilities, competencies and team engagement, and that appropriate launch preparations are executed in a timely way | | | | ||||
PBC Commercial Program | | | 25% | | | 30% | |
Includes specified commercial milestone as follows: | | | | ||||
• achieve pre-specified Ocaliva total unit sales for 2020 | | | | ||||
Pipeline | | | 15% | | | 15% | |
Includes specified activities and milestones related to: | | | | | | | |
• manufacturing selected fixed-dose combination (“FDC”) formulation for potential use and study • timing and completion of key activities required to prepare for first-in-human clinical trial of INT-787 | | | | ||||
Organization | | | 10% | | | 10% | |
Includes specified activities and milestones related to: | | | | | | | |
• effective organizational management related to human resources, capabilities, and competencies for executing on organizational priorities, including potential launch of OCA for liver fibrosis due to NASH • recruiting and training of appropriate staff • appropriate management of expenses and headcount | | | | | | ||
Total | | | 100% | | | 70% | |
| | | 2020 Cash Incentive Bonus | | |||||||||||||||||||||||||||
Named Executive Officer | | | Target (as % of Base Salary) | | | Corporate Goal Achievement Level | | | Individual Goal Achievement Level | | | Aggregate Achievement (as % of Base Salary) | | | Payment ($) | | |||||||||||||||
Mark Pruzanski, M.D. | | | | | 70% | | | | | | N/A | | | | | | — | | | | | | N/A | | | | | | 531,995(1) | | |
Jerome Durso | | | | | 50% | | | | | | 70% | | | | | | 110% | | | | | | 39% | | | | | | 231,737 | | |
Sandip Kapadia | | | | | 50% | | | | | | 70% | | | | | | 110% | | | | | | 39% | | | | | | 184,039 | | |
Richard Kim | | | | | 50% | | | | | | 70% | | | | | | 105% | | | | | | 37% | | | | | | 168,056 | | |
Lisa Bright | | | | | 50% | | | | | | — | | | | | | — | | | | | | — | | | | | | 240,955(2) | | |
Ryan Sullivan | | | | | 50% | | | | | | — | | | | | | — | | | | | | — | | | | | | —(3) | | |
Christian Weyer, M.D., M.A.S. | | | | | 50% | | | | | | 70% | | | | | | 100% | | | | | | 35% | | | | | | 170,804 | | |
Goal | | | Weight | | | Performance Score | | | Weighted Performance | | |||||||||
Achieve PBC net sales of $332.5 million | | | | | 50% | | | | | | 117.80% | | | | | | 29.45% | | |
Achieve PBC commercial contribution of $102 million | | | | | 15% | | | | | | 200.00% | | | | | | 15.00% | | |
Complete enrollment for Study 213 by year-end | | | | | 10% | | | | | | 44.40% | | | | | | 2.22% | | |
Deliver first topline results from Study 123 by year-end | | | | | 10% | | | | | | 0.00% | | | | | | 0.00% | | |
Achieve regulatory alignment on post-marketing commitments for PBC by year-end | | | | | 15% | | | | | | 100.00% | | | | | | 7.50% | | |
PBC total | | | | | 50% | | | | | | 108.34% | | | | | | 54.17% | | |
Advance the delivery of the analyses necessary to support the decision-making process on OCA in NASH by year-end | | | | | 60% | | | | | | 75.00% | | | | | | 18.00% | | |
Achieve last patient visit in REVERSE/Study 304 by end Q3 2021 | | | | | 20% | | | | | | 100.00% | | | | | | 8.00% | | |
Deliver topline safety and efficacy readout of REVERSE/Study 304 by year-end | | | | | 20% | | | | | | 0.00% | | | | | | 0.00% | | |
NASH total | | | | | 40% | | | | | | 65.00% | | | | | | 26.00% | | |
Strategy and pipeline goals including commencing first in human study of INT-787 by year-end | | | | | 100% | | | | | | 100.00% | | | | | | 10.00% | | |
Strategy and pipeline total | | | | | 10% | | | | | | 100.00% | | | | | | 10.00% | | |
Total | | | | | 100% | | | | | | 90.17% | | | | | | 90.17% | | |
| | | 2021 | | | 2022 Target | | ||||||||||||||||||||||||||||||
Name | | | Target | | | Corporate Performance | | | Individual Performance | | | Payout | | | Payout ($) | | |||||||||||||||||||||
Jerome Durso | | | | | 70% | | | | | | 90.17% | | | | | | N/A | | | | | | 63.119% | | | | | | 435,994.49 | | | | | | 70% | | |
Andrew Saik | | | | | 50% | | | | | | 90.17% | | | | | | 100% | | | | | | 45.085% | | | | | | 113,822.72 | | | | | | 50% | | |
Sandip Kapadia | | | | | N/A | | | | | | N/A | | | | | | N/A | | | | | | N/A | | | | | | N/A | | | | | | N/A | | |
Rocco Venezia | | | | | 40% | | | | | | 90.17% | | | | | | 100% | | | | | | 36.068% | | | | | | 131,648.20 | | | | | | 50% | | |
Jared Freedberg | | | | | 50% | | | | | | 90.17% | | | | | | 100% | | | | | | 45.085% | | | | | | 208,112.36 | | | | | | 50% | | |
Michelle Berrey | | | | | 50% | | | | | | 90.17% | | | | | | 100% | | | | | | 45.085% | | | | | | 148,969.86 | | | | | | 50% | | |
Gail Cawkwell | | | | | 50% | | | | | | 90.17% | | | | | | 100% | | | | | | 45.085% | | | | | | 216,385.46 | | | | | | 50% | | |
| | | 2021 | | | 2022 | | ||||||||||||||||||||||||||||||
Name | | | Options | | | RSUs | | | PSUs | | | Options | | | RSUs | | | PSUs | | ||||||||||||||||||
Jerome Durso | | | | | 72,000 | | | | | | 46,000 | | | | | | 110,300 | | | | | | 60,900 | | | | | | 35,700 | | | | | | 107,000 | | |
Andrew Saik | | | | | 72,540 | | | | | | 52,156 | | | | | | — | | | | | | 17,600 | | | | | | 10,300 | | | | | | 10,300 | | |
Sandip Kapadia | | | | | 26,900 | | | | | | 17,200 | | | | | | 13,800 | | | | | | — | | | | | | — | | | | | | — | | |
Rocco Venezia | | | | | 5,500 | | | | | | 3,438 | | | | | | — | | | | | | 6,100 | | | | | | 3,600 | | | | | | 3,600 | | |
Jared Freedberg | | | | | 69,400 | | | | | | 44,277 | | | | | | — | | | | | | 17,600 | | | | | | 10,300 | | | | | | 10,300 | | |
Michelle Berrey | | | | | 93,000 | | | | | | 67,118 | | | | | | — | | | | | | 17,600 | | | | | | 10,300 | | | | | | 10,300 | | |
Gail Cawkwell | | | | | 19,700 | | | | | | 12,600 | | | | | | 10,100 | | | | | | 11,300 | | | | | | 6,600 | | | | | | 6,600 | | |
Named Executive Officer | | | TSR PSUs | | | Stock Options | | | Restricted Stock Units | | |||||||||
Mark Pruzanski, M.D. | | | | | 25,800 | | | | | | 17,700 | | | | | | 10,800 | | |
Jerome Durso | | | | | 8,500 | | | | | | 17,400 | | | | | | 10,600 | | |
Sandip Kapadia | | | | | 4,500 | | | | | | 9,200 | | | | | | 5,600 | | |
Richard Kim | | | | | 4,300 | | | | | | 8,800 | | | | | | 5,400 | | |
Lisa Bright | | | | | 3,800 | | | | | | 7,900 | | | | | | 4,800 | | |
Ryan Sullivan | | | | | 4,500 | | | | | | 9,200 | | | | | | 5,600 | | |
Christian Weyer, M.D., M.A.S. | | | | | 3,800 | | | | | | 7,900 | | | | | | 4,800 | | |
Named Executive Officer | | | 2021 Salary | | | 2020 Salary | | | Change from 2020 | | |||||||||
Jerome Durso | | | | $ | 690,750 | | | | | $ | 601,913 | | | | | | 14.76% | | |
Sandip Kapadia* | | | | $ | 497,140 | | | | | $ | 478,023 | | | | | | 4.00% | | |
Richard Kim* | | | | $ | 457,294 | | | | | $ | 457,294 | | | | | | — | | |
Christian Weyer, M.D., M.A.S. | | | | $ | 504,000 | | | | | $ | 488,011 | | | | | | 3.28% | | |
Named Executive Officer | | | TSR PSUs | | | Stock Options | | | Restricted Stock Units | | |||||||||
Jerome Durso | | | | | 110,300 | | | | | | 72,000 | | | | | | 46,000 | | |
Sandip Kapadia* | | | | | 13,800 | | | | | | 26,900 | | | | | | 17,200 | | |
Richard Kim* | | | | | — | | | | | | — | | | | | | — | | |
Christian Weyer, M.D., M.A.S. | | | | | 10,100 | | | | | | 19,700 | | | | | | 12,600 | | |
Name and Principal Position | | Year(1) | | Salary ($)(2) | | Bonus ($)(3) | | Stock Awards ($)(4) | | Option Awards ($)(4) | | Non-Equity Incentive Plan Compensation ($)(5) | | All Other Compensation ($)(6) | | Total ($) | | | Year | | Salary ($) | | Bonus ($)(2) | | Stock Awards ($)(3) | | Option Awards ($)(3) | | Non-Equity Incentive Plan Compensation ($)(4) | | All Other Compensation ($)(5) | | Total ($) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mark Pruzanski, M.D., President and Chief Executive Officer | | | | | 2020 | | | | | 757,850 | | | | | — | | | | | 4,113,504 | | | | | 1,015,996 | | | | | 531,995 | | | | | 7,660 | | | | | 6,427,005 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2019 | | | | | 734,292 | | | | | — | | | | | 4,197,742 | | | | | 1,116,118 | | | | | 560,265 | | | | | 7,368 | | | | | 6,615,785 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2018 | | | | | 702,000 | | | | | — | | | | | 1,667,718 | | | | | 1,705,358 | | | | | 442,260 | | | | | 8,623 | | | | | 4,525,960 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jerome Durso, Chief Operating Officer | | | | | 2020 | | | | | 599,524 | | | | | — | | | | | 2,057,016 | | | | | 998,776 | | | | | 231,737 | | | | | 21,910 | | | | | 3,908,963 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2019 | | | | | 573,250 | | | | | — | | | | | 2,089,570 | | | | | 1,238,321 | | | | | 359,284 | | | | | 21,368 | | | | | 4,281,793 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2018 | | | | | 540,800 | | | | | — | | | | | 1,554,326 | | | | | 775,844 | | | | | 292,032 | | | | | 22,403 | | | | | 3,185,406 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sandip Kapadia, Chief Financial Officer and Treasurer | | | | | 2020 | | | | | 476,863 | | | | | — | | | | | 1,087,836 | | | | | 528,088 | | | | | 184,039 | | | | | 21,910 | | | | | 2,298,736 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2019 | | | | | 464,100 | | | | | — | | | | | 1,001,664 | | | | | 586,573 | | | | | 252,935 | | | | | 21,368 | | | | | 2,326,640 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2018 | | | | | 442,000 | | | | | — | | | | | 790,164 | | | | | 393,544 | | | | | 228,735 | | | | | 22,403 | | | | | 1,876,846 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Richard Kim, Former President, U.S. Commercial & Strategic Marketing | | | | | 2020 | | | | | 456,095 | | | | | — | | | | | 1,044,360 | | | | | 505,128 | | | | | 168,056 | | | | | 79,211 | | | | | 2,252,850 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2019 | | | | | 442,900 | | | | | 202,800 | | | | | 890,368 | | | | | 521,398 | | | | | 265,519 | | | | | 76,343 | | | | | 2,399,328 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lisa Bright, Former President, International (7) | | | | 2020 | | | | | 480,552 | | | | | — | | | | | 925,704 | | | | | 453,467 | | | | | 240,955 | | | | | 139,106 | | | | | 2,239,784 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ryan Sullivan, Former General Counsel and Secretary | | | | | 2020 | | | | | 437,107 | | | | | — | | | | | 1,087,836 | | | | | 528,088 | | | | | — | | | | | 89,942 | | | | | 2,142,973 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2019 | | | | | 445,520 | | | | | — | | | | | 1,471,902 | | | | | 871,713 | | | | | 267,089 | | | | | 21,368 | | | | | 3,077,592 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2018 | | | | | 376,158 | | | | | — | | | | | 1,239,112 | | | | | 1,190,351 | | | | | 229,122 | | | | | 173,437 | | | | | 3,208,180 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Christian Weyer, M.D., M.A.S., EVP, Research & Development | | | | 2020 | | | | | 486,731 | | | | | — | | | | | 925,704 | | | | | 453,467 | | | | | 170,804 | | | | | 21,910 | | | | | 2,058,616 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jerome Durso, President & CEO | | | | | 2021 | | | | | 690,750 | | | | | — | | | | | 5,474,865 | | | | | 1,234,800 | | | | | 435,994 | | | | | 33,945 | | | | | 7,870,354 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2020 | | | | | 599,524 | | | | | — | | | | | 2,057,016 | | | | | 998,776 | | | | | 231,737 | | | | | 21,910 | | | | | 3,908,963 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2019 | | | | | 573,250 | | | | | — | | | | | 2,089,570 | | | | | 1,238,321 | | | | | 359,284 | | | | | 21,368 | | | | | 4,281,793 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Andrew Saik, CFO | | | | 2021 | | | | | 251,894 | | | | | 102,500 | | | | | 1,086,931 | | | | | 903,848 | | | | | 113,823 | | | | | 16,857 | | | | | 2,475,854 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sandip Kapadia, Former CFO | | | | | 2021 | | | | | 117,513 | | | | | — | | | | | 1,022,142 | | | | | 461,335 | | | | | — | | | | | 59,674 | | | | | 1,660,664 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2020 | | | | | 476,863 | | | | | — | | | | | 1,087,836 | | | | | 528,088 | | | | | 184,039 | | | | | 21,910 | | | | | 2,298,736 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2019 | | | | | 464,100 | | | | | — | | | | | 1,001,664 | | | | | 586,573 | | | | | 252,935 | | | | | 21,368 | | | | | 2,326,640 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rocco Venezia, Interim CFO & Chief Accounting Officer | | | | 2021 | | | | | 354,554 | | | | | 154,000 | | | | | 101,283 | | | | | 94,325 | | | | | 131,648 | | | | | 20,423 | | | | | 856,234 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jared Freedberg, General Counsel | | | | 2021 | | | | | 423,133 | | | | | — | | | | | 1,633,821 | | | | | 1,487,242 | | | | | 208,112 | | | | | 21,714 | | | | | 3,774,023 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Michelle Berrey, President of R&D and Chief Medical Officer | | | | 2021 | | | | | 329,545 | | | | | — | | | | | 1,434,983 | | | | | 1,186,680 | | | | | 148,970 | | | | | 18,321 | | | | | 3,118,499 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gail Cawkwell, SVP Medical Affairs, Safety & Pharmacovigilance | | | | 2021 | | | | | 478,412 | | | | | 750,000 | | | | | 748,431 | | | | | 337,855 | | | | | 216,385 | | | | | 31,244 | | | | | 2,562,328 | | |
Name | | | Contributions Under Retirement Plans ($)(i) | | | Health Insurance ($)(ii) | | | Miscellaneous ($) | | |||||||||
Mark Pruzanski, M.D. | | | | | — | | | | | | 7,660 | | | | | | — | | |
Jerome Durso | | | | | 14,250 | | | | | | 7,660 | | | | | | — | | |
Sandip Kapadia | | | | | 14,250 | | | | | | 7,660 | | | | | | — | | |
Richard Kim(iii) | | | | | 14,250 | | | | | | 7,660 | | | | | | 57,301 | | |
Lisa Bright(iv) | | | | | 86,499 | | | | | | 18,168 | | | | | | 34,439 | | |
Ryan Sullivan(v) | | | | | 14,250 | | | | | | 7,660 | | | | | | 68,032 | | |
Christian Weyer, M.D., M.A.S. | | | | | 14,250 | | | | | | 7,660 | | | | | | — | | |
Name | | | Contributions Under Retirement Plans ($)(i) | | | Health Insurance ($)(ii) | | | Miscellaneous | | |||||||||
Jerome Durso | | | | | 14,500 | | | | | | 7,870 | | | | | | 11,575 | | |
Andrew Saik | | | | | 12,595 | | | | | | 4,263 | | | | | | — | | |
Sandip Kapadia | | | | | — | | | | | | 1,967 | | | | | | 57,706 | | |
Rocco Venezia | | | | | 14,500 | | | | | | — | | | | | | 5,923 | | |
Jared Freedberg | | | | | 14,500 | | | | | | 7,214 | | | | | | — | | |
Michelle Berrey | | | | | 14,500 | | | | | | 3,822 | | | | | | — | | |
Gail Cawkwell | | | | | 14,500 | | | | | | 7,870 | | | | | | 8,875 | | |
Name | | Grant Date(1) | | Estimated Future Payout Under Non-Equity Incentive Plan Awards Target ($)(2) | | | Estimated Future Payouts Under Equity Incentive Plan Awards(3) | | | All Other Stock Awards: Number of Shares of Stock (#)(5) | | All Other Option Awards: Number of Securities Underlying Options (#)(6) | | Exercise or Base Price of Option Awards ($/Sh)(7) | | Grant Date Fair Value of Stock and Option Awards ($)(8) | | | Grant Date(1) | | Estimated Future Payout Under Non-Equity Incentive Plan Awards Target ($)(2) | | | Estimated Future Payouts Under Equity Incentive Plan Awards(3) | | | All Other Stock Awards: Number of Shares of Stock (#)(4) | | All Other Option Awards: Number of Securities Underlying Options (#)(5) | | Exercise or Base Price of Option Awards ($/Sh)(6) | | Grant Date Fair Value of Stock and Option Awards ($)(7) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Threshold (#)(4) | | Target (#) | | Maximum (#) | | | Threshold (#) | | Target (#) | | Maximum (#) | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mark Pruzanski, M.D. | | | | | — | | | | | 531,995 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | 12,900 | | | | | 25,800 | | | | | 38,700 | | | | | — | | | | | — | | | | | — | | | | | 3,037,176 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 10,800 | | | | | — | | | | | — | | | | | 1,076,328 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 17,700 | | | | | 57.40 | | | | | 1,015,996 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jerome Durso | | | | | — | | | | | 300,956 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | — | | | | | 483,525 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | 4,250 | | | | | 8,500 | | | | | 12,750 | | | | | — | | | | | — | | | | | — | | | | | 1,000,620 | | | | | | 01/22/21 | | | | | — | | | | | 55,150 | | | | | 110,300 | | | | | 165,450 | | | | | — | | | | | — | | | | | — | | | | | 4,119,705 | | | |||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 10,600 | | | | | — | | | | | — | | | | | 1,056,396 | | | | | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 46,000 | | | | | — | | | | | — | | | | | 1,355,160 | | | |||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 17,400 | | | | | 57.40 | | | | | 998,776 | | | | | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 72,000 | | | | | 29.46 | | | | | 1,234,800 | | | |||||||||||||||||||
Andrew Saik | | | | | — | | | | | 237,500 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 06/21/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 06/21/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 52,156 | | | | | — | | | | | — | | | | | 1,086,931 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 06/21/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 72,540 | | | | | 20.84 | | | | | 903,848 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sandip Kapadia | | | | | — | | | | | 239,012 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | 2,250 | | | | | 4,500 | | | | | 6,750 | | | | | — | | | | | — | | | | | — | | | | | 529,740 | | | | | | 01/22/21 | | | | | — | | | | | 6,900 | | | | | 13,800 | | | | | 20,700 | | | | | — | | | | | — | | | | | — | | | | | 515,430 | | | |||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 5,600 | | | | | — | | | | | — | | | | | 558,096 | | | | | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 17,200 | | | | | — | | | | | — | | | | | 506,712 | | | |||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 9,200 | | | | | 57.40 | | | | | 528,088 | | | | | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 26,900 | | | | | 29.46 | | | | | 461,335 | | | |||||||||||||||||||
Richard Kim | | | | | — | | | | | 228,647 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | 2,150 | | | | | 4,300 | | | | | 6,450 | | | | | — | | | | | — | | | | | — | | | | | 506,196 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 5,400 | | | | | — | | | | | — | | | | | 538,164 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 8,800 | | | | | 57.40 | | | | | 505,128 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lisa Bright | | | | | — | | | | | 240,955 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | 1,900 | | | | | 3,800 | | | | | 5,700 | | | | | — | | | | | — | | | | | — | | | | | 447,336 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 4,800 | | | | | — | | | | | — | | | | | 478,368 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 7,900 | | | | | 57.40 | | | | | 453,467 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ryan Sullivan | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | 2,250 | | | | | 4,500 | | | | | 6,750 | | | | | — | | | | | — | | | | | — | | | | | 529,740 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 5,600 | | | | | — | | | | | — | | | | | 558,096 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 9,200 | | | | | 57.40 | | | | | 528,088 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Christian Weyer, M.D., M.A.S | | | | | — | | | | | 244,006 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | 1,900 | | | | | 3,800 | | | | | 5,750 | | | | | — | | | | | — | | | | | — | | | | | 447,336 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 4,800 | | | | | — | | | | | — | | | | | 478,368 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 7,900 | | | | | 57.40 | | | | | 453,467 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rocco Venezia | | | | | — | | | | | 146,000 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 3,438 | | | | | — | | | | | — | | | | | 101,283 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 5,500 | | | | | 29.46 | | | | | 94,325 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jared Freedberg | | | | | — | | | | | 230,800 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/01/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/01/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 44,277 | | | | | — | | | | | — | | | | | 1,633,821 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/01/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 69,400 | | | | | 36.90 | | | | | 1,487,242 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Michelle Berrey | | | | | — | | | | | 300,000 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 06/14/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 06/14/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 67,118 | | | | | — | | | | | — | | | | | 1,434,983 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 06/14/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 93,000 | | | | | 21.38 | | | | | 1,186,680 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gail Cawkwell | | | | | — | | | | | 239,975 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/22/21 | | | | | — | | | | | 5,050 | | | | | 10,100 | | | | | 15,150 | | | | | — | | | | | — | | | | | — | | | | | 377,235 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 12,600 | | | | | — | | | | | — | | | | | 371,196 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 19,700 | | | | | 29.46 | | | | | 337,855 | | |
| | | Option awards | | | | Stock awards | | ||||||||||||||||||||||||||||||||||||||||||||||||
Name | | | Number of securities underlying unexercised options (#) exercisable | | | Number of securities underlying unexercised options (#) unexercisable(1) | | | Equity incentive plan awards: number of securities underlying unexercised unearned options (#) | | | Option exercise price ($) | | | Option expiration date | | | | Number of shares or units of stock that have not vested (#)(2) | | | Market value of shares or units of stock that have not vested ($) | | | Equity incentive plan awards: number of unearned shares, units or other rights that have not vested (#)(3) | | | Equity incentive plan awards: market or payout value of unearned shares, units or other rights that have not vested ($) | | |||||||||||||||||||||||||||
(a) | | | (b) | | | (c) | | | (d) | | | (e) | | | (f) | | | | (g) | | | (h) | | | (i) | | | (j) | | |||||||||||||||||||||||||||
Mark Pruzanski, M.D.(7) | | | | | 30,084(4a) | | | | | | — | | | | | | — | | | | | | 21.50 | | | | | | 11/16/22 | | | | | | | 1,450(5a) | | | | | | 35,815 | | | | | | 32,039(6a) | | | | | | 791,363 | | |
| | | | | 62,595(4b) | | | | | | — | | | | | | — | | | | | | 31.90 | | | | | | 05/07/23 | | | | | | | 3,896(5e) | | | | | | 96,231 | | | | | | 35,475(6b) | | | | | | 876,233 | | |
| | | | | 5,733(4c) | | | | | | — | | | | | | — | | | | | | 266.01 | | | | | | 04/11/24 | | | | | | | 7,425(5f) | | | | | | 183,398 | | | | | | — | | | | | | — | | |
| | | | | 32,550(4d) | | | | | | — | | | | | | — | | | | | | 161.16 | | | | | | 10/01/25 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 30,500(4e) | | | | | | — | | | | | | — | | | | | | 94.29 | | | | | | 02/11/26 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 39,167(4f) | | | | | | 833 | | | | | | — | | | | | | 107.18 | | | | | | 02/01/27 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 34,123(4g) | | | | | | 11,377 | | | | | | — | | | | | | 58.74 | | | | | | 02/05/28 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 7,420(4h) | | | | | | 6,280 | | | | | | — | | | | | | 110.80 | | | | | | 01/16/29 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 5,531(4i) | | | | | | 12,169 | | | | | | — | | | | | | 99.66 | | | | | | 01/23/30 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Jerome Durso | | | | | 19,167(4j) | | | | | | 833 | | | | | | — | | | | | | 115.93 | | | | | | 02/23/27 | | | | | | | 937(5b) | | | | | | 23,144 | | | | | | 3,750(6a) | | | | | | 92,625 | | |
| | | | | 15,093(4g) | | | | | | 5,607 | | | | | | — | | | | | | 58.74 | | | | | | 02/05/28 | | | | | | | 4,250(5d) | | | | | | 104,975 | | | | | | 4,250(6b) | | | | | | 104,975 | | |
| | | | | 7,600(4h) | | | | | | 7,600 | | | | | | — | | | | | | 110.80 | | | | | | 01/16/29 | | | | | | | 4,700(5e) | | | | | | 116,090 | | | | | | — | | | | | | — | | |
| | | | | 4,350(4i) | | | | | | 13,050 | | | | | | — | | | | | | 99.66 | | | | | | 01/23/30 | | | | | | | 7,950(5f) | | | | | | 196,365 | | | | | | — | | | | | | — | | |
Sandip Kapadia | | | | | 18,000(4k) | | | | | | — | | | | | | — | | | | | | 146.36 | | | | | | 07/01/26 | | | | | | | 437(5a) | | | | | | 10,794 | | | | | | 1,800(6a) | | | | | | 44,460 | | |
| | | | | 11,358(4f) | | | | | | 242 | | | | | | — | | | | | | 107.18 | | | | | | 02/01/27 | | | | | | | 2,157(5d) | | | | | | 53,278 | | | | | | 2,250(6b) | | | | | | 55,575 | | |
| | | | | 7,655(4g) | | | | | | 2,845 | | | | | | — | | | | | | 58.74 | | | | | | 02/05/28 | | | | | | | 2,250(5e) | | | | | | 55,575 | | | | | | — | | | | | | — | | |
| | | | | 3,600(4h) | | | | | | 3,600 | | | | | | — | | | | | | 110.80 | | | | | | 01/16/29 | | | | | | | 4,200(5f) | | | | | | 103,740 | | | | | | — | | | | | | — | | |
| | | | | 2,300(4i) | | | | | | 6,900 | | | | | | — | | | | | | 99.66 | | | | | | 01/23/30 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Richard Kim | | | | | 4,395(4L) | | | | | | — | | | | | | — | | | | | | 277.61 | | | | | | 07/18/25 | | | | | | | 294(5a) | | | | | | 7,262 | | | | | | 1,600(6a) | | | | | | 39,520 | | |
| | | | | 4,100(4e) | | | | | | — | | | | | | — | | | | | | 94.29 | | | | | | 02/11/26 | | | | | | | 1,813(5d) | | | | | | 44,781 | | | | | | 2,150(6b) | | | | | | 53,105 | | |
| | | | | 7,313(4f) | | | | | | 487 | | | | | | — | | | | | | 107.18 | | | | | | 02/01/27 | | | | | | | 2,000(5e) | | | | | | 49,400 | | | | | | — | | | | | | — | | |
| | | | | 6,416(4g) | | | | | | 2,384 | | | | | | — | | | | | | 58.74 | | | | | | 02/05/28 | | | | | | | 4,050(5f) | | | | | | 100,035 | | | | | | — | | | | | | — | | |
| | | | | 3,200(4h) | | | | | | 3,200 | | | | | | — | | | | | | 110.80 | | | | | | 01/16/29 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 2,200(4i) | | | | | | 6,600 | | | | | | — | | | | | | 99.66 | | | | | | 01/23/30 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Lisa Bright(8) | | | | | 10,232(4m) | | | | | | — | | | | | | — | | | | | | 155.00 | | | | | | 01/01/22 | | | | | | | 294(5a) | | | | | | 7,262 | | | | | | 1,300(6a) | | | | | | 32,110 | | |
| | | | | 13,450(4d) | | | | | | — | | | | | | — | | | | | | 161.16 | | | | | | 01/01/22 | | | | | | | 1,719(5d) | | | | | | 42,459 | | | | | | 1,900(6b) | | | | | | 46,930 | | |
| | | | | 10,200(4e) | | | | | | — | | | | | | — | | | | | | 94.29 | | | | | | 01/01/22 | | | | | | | 1,650(5e) | | | | | | 40,755 | | | | | | — | | | | | | — | | |
| | | | | 7,638(4f) | | | | | | 162 | | | | | | — | | | | | | 107.18 | | | | | | 01/01/22 | | | | | | | 3,600(5f) | | | | | | 88,920 | | | | | | — | | | | | | — | | |
| | | | | 6,052(4g) | | | | | | 2,248 | | | | | | — | | | | | | 58.74 | | | | | | 01/01/22 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 2,650(4h) | | | | | | 2,650 | | | | | | — | | | | | | 110.80 | | | | | | 01/01/22 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 1,975(4i) | | | | | | 5,925 | | | | | | — | | | | | | 99.66 | | | | | | 01/01/22 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Ryan Sullivan(8) | | | | | 15,443(4n) | | | | | | — | | | | | | — | | | | | | 53.41 | | | | | | 03/11/21 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 5,127(4h) | | | | | | — | | | | | | — | | | | | | 110.80 | | | | | | 03/11/21 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Christian Weyer, M.D., M.A.S. | | | | | 11,504(4o) | | | | | | 5,730 | | | | | | — | | | | | | 59.12 | | | | | | 11/27/27 | | | | | | | 4,125(5c) | | | | | | 101,888 | | | | | | 1,700(6a) | | | | | | 41,990 | | |
| | | | | 2,015(4g) | | | | | | 868 | | | | | | — | | | | | | 58.74 | | | | | | 02/05/28 | | | | | | | 657(5d) | | | | | | 16,228 | | | | | | 1,900(6b) | | | | | | 46,930 | | |
| | | | | 3,400(4h) | | | | | | 3,400 | | | | | | — | | | | | | 110.80 | | | | | | 01/16/29 | | | | | | | 2,100(5e) | | | | | | 51,870 | | | | | | — | | | | ��� | | — | | |
| | | | | 1,975(4i) | | | | | | 5,925 | | | | | | — | | | | | | 99.66 | | | | | | 01/23/30 | | | | | | | 3,600(5f) | | | | | | 89,920 | | | | | | — | | | | | | — | | |
| | | Option awards | | | | Stock awards | | ||||||||||||||||||||||||||||||||||||||||||||||||
Name | | | Number of securities underlying unexercised options (#) exercisable(2) | | | Number of securities underlying unexercised options (#) unexercisable(2)(3) | | | Equity incentive plan awards: number of securities underlying unexercised unearned options (#) | | | Option exercise price ($) | | | Option expiration date | | | | Number of shares or units of stock that have not vested (#)(3)(4) | | | Market value of shares or units of stock that have not vested ($) | | | Equity incentive plan awards: number of unearned shares, units or other rights that have not vested (#)(3)(5)(6) | | | Equity incentive plan awards: market or payout value of unearned shares, units or other rights that have not vested ($)(6) | | |||||||||||||||||||||||||||
(a) | | | (b) | | | (c) | | | (d) | | | (e) | | | (f) | | | | (g) | | | (h) | | | (i) | | | (j) | | |||||||||||||||||||||||||||
Jerome Durso | | | | | 20,000(a) | | | | | | — | | | | | | — | | | | | | 115.93 | | | | | | 02/23/27 | | | | | | | 850(a) | | | | | | 13,847 | | | | | | 3,750(a) | | | | | | 61,088 | | |
| | | 20,267(b) | | | | | | 433 | | | | | | — | | | | | | 58.74 | | | | | | 02/05/28 | | | | | | | 2,350(b) | | | | | | 38,282 | | | | | | 4,250(b) | | | | | | 69,233 | | | ||
| | | 11,400(c) | | | | | | 3,800 | | | | | | — | | | | | | 110.80 | | | | | | 01/16/29 | | | | | | | 5,300(c) | | | | | | 86,337 | | | | | | 55,150(c) | | | | | | 898,394 | | | ||
| | | 8,700(d) | | | | | | 8,700 | | | | | | — | | | | | | 99.66 | | | | | | 01/23/30 | | | | | | | 34,500(d) | | | | | | 562,005 | | | | | | — | | | | | | — | | | ||
| | | 18,000(e) | | | | | | 54,000 | | | | | | — | | | | | | 29.46 | | | | | | 01/22/31 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
Andrew Saik | | | | | —(f) | | | | | | 72,540 | | | | | | — | | | | | | 20.84 | | | | | | 06/21/31 | | | | | | | 52,156(e) | | | | | | 849,621 | | | | | | — | | | | | | — | | |
Sandip Kapadia(1) | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Rocco Venezia | | | | | 2,050(g) | | | | | | — | | | | | | — | | | | | | 148.73 | | | | | | 07/15/26 | | | | | | | 88(a) | | | | | | 1,434 | | | | | | — | | | | | | — | | |
| | | 1,200(h) | | | | | | — | | | | | | — | | | | | | 112.69 | | | | | | 02/09/27 | | | | | | | 207(b) | | | | | | 3,372 | | | | | | — | | | | | | — | | | ||
| | | 2,153(b) | | | | | | 47 | | | | | | — | | | | | | 58.74 | | | | | | 02/05/28 | | | | | | | 900(c) | | | | | | 14,661 | | | | | | — | | | | | | — | | | ||
| | | 990(c) | | | | | | 330 | | | | | | — | | | | | | 110.80 | | | | | | 01/16/29 | | | | | | | 1,540(f) | | | | | | 25,087 | | | | | | — | | | | | | — | | | ||
| | | 1,475(d) | | | | | | 1,475 | | | | | | — | | | | | | 99.66 | | | | | | 01/23/30 | | | | | | | 2,579(d) | | | | | | 42,012 | | | | | | — | | | | | | — | | | ||
| | | 1,375(e) | | | | | | 4,125 | | | | | | — | | | | | | 29.46 | | | | | | 01/22/31 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
Jared Freedberg | | | | | —(i) | | | | | | 69,400 | | | | | | — | | | | | | 36.90 | | | | | | 02/01/31 | | | | | | | 44,277(g) | | | | | | 721,272 | | | | | | — | | | | | | — | | |
Michelle Berrey | | | | | —(j) | | | | | | 93,000 | | | | | | — | | | | | | 21.38 | | | | | | 06/14/31 | | | | | | | 67,118(h) | | | | | | 1,093,352 | | | | | | — | | | | | | — | | |
Gail Cawkwell | | | | | 19,823(k) | | | | | | 956 | | | | | | — | | | | | | 54.63 | | | | | | 02/12/28 | | | | | | | 940(i) | | | | | | 15,313 | | | | | | 1,650(a) | | | | | | 26,879 | | |
| | | 5,025(c) | | | | | | 1,675 | | | | | | — | | | | | | 110.80 | | | | | | 01/16/29 | | | | | | | 1,025(a) | | | | | | 16,697 | | | | | | 1,700(b) | | | | | | 27,693 | | | ||
| | | 3,450(d) | | | | | | 3,450 | | | | | | — | | | | | | 99.66 | | | | | | 01/23/30 | | | | | | | 2,100(b) | | | | | | 34,209 | | | | | | 5,050(c) | | | | | | 82,265 | | | ||
| | | 4,925(e) | | | | | | 14,775 | | | | | | — | | | | | | 29.46 | | | | | | 01/22/31 | | | | | | | 9,450(c) | | | | | | 153,941 | | | | | | — | | | | | | — | | |
Option | | | Grant Date | | | Vesting Commencement Date | | ||||||
(a) | | | | | | | | | | — | | | |
(b) | |||||||||||||
| | | | 02/05/18 | | | | | | 01/01/18 | | | |
| | | | 01/16/19 | | | | | | 01/01/19 | | | |
| | | | 01/23/20 | | | | | | 01/ | | | |
| | | | | | | | | | | |||
| | | | 06/21/21 | | | | | | 06/21/21 | | | |
(g) | | | | | 07/ | | | | | | — | | |
| | | | | | | | | — | | | ||
| | | | | | | | | | | |||
| | | | 06/14/21 | | | | | | 06/14/21 | | | |
(k) | | | | | 02/ | | | | | | 02/ | ||
| |
Shares or Units | | | Grant Date | | | Vesting Commencement Date | | ||||||
(a) | | | | | 02/ | ||||||||
| | | | | 01/01/18 | | | ||||||
| | | | 01/16/19 | | | | | | 01/01/19 | | | |
| | | | 01/23/20 | | | | | | 01/01/20 | | | |
(d) | | | | | 01/22/21 | | | | | | 01/01/21 | | |
(e) | | | | | 06/21/21 | | | | | | 06/21/21 | | |
(f) | | | | | 09/01/20 | | | | | | 09/01/20 | | |
(g) | | | | | 02/01/21 | | | | | | 02/01/21 | | |
(h) | | | | | 06/14/21 | | | | | | 06/14/21 | | |
(i) | | | | | 02/12/18 | | | | | | 02/12/18 | | |
Shares or Units | | | Grant Date | | | Vesting Commencement Date | | ||||||
(a) | | | | | 01/16/19 | | | | | | 01/01/19 | | |
(b) | | | | | 01/23/20 | | | | | | 01/01/20 | | |
(c) | | | | | 01/22/21 | | | | | | 01/01/21 | | |
| | | Option Awards | | | Stock Awards | | ||||||||||||||||||
Name | | | Number of Shares Acquired on Exercise (#) | | | Value Realized on Exercise ($) | | | Number of Shares Acquired on Vesting (#) | | | Value Realized on Vesting ($)(1) | | ||||||||||||
Mark Pruzanski, M.D. | | | | | — | | | | | | — | | | | | | 54,346 | | | | | | 1,736,397 | | |
Jerome Durso | | | | | — | | | | | | — | | | | | | 12,150 | | | | | | 596,750 | | |
Sandip Kapadia | | | | | — | | | | | | — | | | | | | 8,812 | | | | | | 512,232 | | |
Richard Kim | | | | | — | | | | | | — | | | | | | 5,102 | | | | | | 251,635 | | |
Lisa Bright | | | | | — | | | | | | — | | | | | | 5,062 | | | | | | 283,113 | | |
Ryan Sullivan | | | | | — | | | | | | — | | | | | | 5,800 | | | | | | 390,775 | | |
Christian Weyer, M.D., M.A.S. | | | | | — | | | | | | — | | | | | | 6,900 | | | | | | 344,750 | | |
| | | Option Awards | | | Stock Awards | | ||||||||||||||||||
Name | | | Number of Shares Acquired on Exercise (#) | | | Value Realized on Exercise ($) | | | Number of Shares Acquired on Vesting (#) | | | Value Realized on Vesting ($)(1) | | ||||||||||||
Jerome Durso | | | | | — | | | | | | — | | | | | | 20,837 | | | | | | 367,103 | | |
Andrew Saik | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Sandip Kapadia | | | | | — | | | | | | — | | | | | | 869 | | | | | | 21,464 | | |
Rocco Venezia | | | | | — | | | | | | — | | | | | | 3,441 | | | | | | 56,157 | | |
Jared Freedberg | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Michelle Berrey | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Gail Cawkwell | | | | | — | | | | | | — | | | | | | 8,981 | | | | | | 163,418 | | |
| | | Termination Due to Death or Disability ($) | | | Termination Without Cause or Resignation for Good Reason ($) | | | Termination Without Cause or Resignation for Good Reason in Connection with a Change in Control ($) | | |||||||||
Jerome Durso | | | | | | | | | | | | | | | | | | | |
Cash Payments(1) | | | | | 483,525 | | | | | | 1,174,275 | | | | | | 2,348,550 | | |
Value of Accelerated Vesting(2) | | | | | 1,220,121 | | | | | | 790,065 | | | | | | 1,875,748 | | |
Health Insurance Benefits(3) | | | | | — | | | | | | 36,635 | | | | | | 73,270 | | |
Total | | | | | 1,703,646 | | | | | | 2,000,975 | | | | | | 4,297,568 | | |
Andrew Saik | | | | | | | | | | | | | | | | | | | |
Cash Payments | | | | | — | | | | | | 475,000 | | | | | | 475,000 | | |
Value of Accelerated Vesting | | | | | — | | | | | | 360,547 | | | | | | 849,621 | | |
Health Insurance Benefits | | | | | — | | | | | | 36,635 | | | | | | 36,635 | | |
Total | | | | | — | | | | | | 872,182 | | | | | | 1,361,256 | | |
Rocco Venezia | | | | | | | | | | | | | | | | | | | |
Cash Payments | | | | | — | | | | | | — | | | | | | — | | |
Value of Accelerated Vesting | | | | | — | | | | | | 64,460 | | | | | | 86,565 | | |
Health Insurance Benefits | | | | | — | | | | | | — | | | | | | — | | |
Total | | | | | — | | | | | | 64,460 | | | | | | 86,565 | | |
Jared Freedberg | | | | | | | | | | | | | | | | | | | |
Cash Payments | | | | | — | | | | | | 461,600 | | | | | | 461,600 | | |
Value of Accelerated Vesting | | | | | — | | | | | | 357,500 | | | | | | 721,272 | | |
Health Insurance Benefits | | | | | — | | | | | | 36,635 | | | | | | 36,635 | | |
Total | | | | | — | | | | | | 855,736 | | | | | | 1,219,508 | | |
Michelle Berrey | | | | | | | | | | | | | | | | | | | |
Cash Payments | | | | | — | | | | | | 600,000 | | | | | | 600,000 | | |
Value of Accelerated Vesting | | | | | — | | | | | | 451,950 | | | | | | 1,093,352 | | |
Health Insurance Benefits | | | | | — | | | | | | 32,682 | | | | | | 32,682 | | |
Total | | | | | — | | | | | | 1,084,631 | | | | | | 1,726,034 | | |
Name | | | | Termination Due to Death ($)(4) | | Termination Due to Disability ($)(5) | | Termination Without Cause or Resignation for Good Reason ($)(6) | | Termination Without Cause or Resignation for Good Reason in Connection with a Change in Control ($)(7) | | ||||||||||||||||||||||||
Jerome Durso | | | | | | | | | | | | ||||||||||||||||||||||||
| | Cash Payments(1) | | 300,956 | | 300,956 | | 902,869 | | 1,805,738 | | | Termination Due to Death or Disability ($) | | Termination Without Cause or Resignation for Good Reason ($) | | Termination Without Cause or Resignation for Good Reason in Connection with a Change in Control ($) | | |||||||||||||||||
Gail Cawkwell | | | | | | | | | | | | | | | | | |||||||||||||||||||
Cash Payments | | | | — | | | | | 719,925 | | | | | 719,925 | | | |||||||||||||||||||
Value of Accelerated Vesting | | | | 218,286 | | | | | 111,994 | | | | | 327,778 | | | |||||||||||||||||||
Health Insurance Benefits | | | | — | | | | | 36,635 | | | | | 36,635 | | | |||||||||||||||||||
Total | | | | 218,286 | | | | | 868,554 | | | | | 1,084,338 | | | |||||||||||||||||||
| | Value of Accelerated Vesting(2) | | 290,225 | | 290,225 | | 351,975 | | 440,574 | | | |||||||||||||||||||||||
| | Health Insurance Benefits(3) | | — | | — | | 35,649 | | 71,298 | | ||||||||||||||||||||||||
| | Total | | 591,181 | | 591,181 | | 1,290,493 | | 2,317,609 | | ||||||||||||||||||||||||
Sandip Kapadia | | | | | | | | | | | | ||||||||||||||||||||||||
| | Cash Payments(1) | | — | | — | | 478,023 | | 478,023 | | ||||||||||||||||||||||||
| | Value of Accelerated Vesting(2) | | 144,495 | | 144,495 | | 104,975 | | 223,387 | | ||||||||||||||||||||||||
| | Health Insurance Benefits(3) | | — | | — | | 35,649 | | 35,649 | | ||||||||||||||||||||||||
| | Total | | 144,495 | | 144,495 | | 618,647 | | 737,059 | | ||||||||||||||||||||||||
Richard Kim | | | | | | | | | | | | ||||||||||||||||||||||||
| | Cash Payments(1) | | — | | — | | 457,294 | | 457,294 | | ||||||||||||||||||||||||
| | Value of Accelerated Vesting(2) | | 132,145 | | 132,145 | | — | | 201,478 | | ||||||||||||||||||||||||
| | Health Insurance Benefits(3) | | — | | — | | 35,649 | | 35,649 | | ||||||||||||||||||||||||
| | Total | | 132,145 | | 132,145 | | 492,943 | | 694,421 | | ||||||||||||||||||||||||
Christian Weyer, M.D., M.A.S. | | | | | | | | | | | | ||||||||||||||||||||||||
| | Cash Payments(1) | | — | | — | | 488,011 | | 488,011 | | ||||||||||||||||||||||||
| | Value of Accelerated Vesting(2) | | 130,910 | | 130,910 | | 68,543 | | 258,905 | | ||||||||||||||||||||||||
| | Health Insurance Benefits(3) | | — | | — | | 35,649 | | 35,649 | | ||||||||||||||||||||||||
| | Total | | 130,910 | | 130,910 | | 592,203 | | 782,565 | |
Plan Category | | | Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants, and Rights | | | Weighted-Average Exercise Price of Outstanding Options, Warrants, and Rights | | | Number of Securities Remaining Available for Future Issuance | | |||||||||
Equity Compensation Plans Approved by Security Holders(1) | | | | | | | | | $ | | | | | | | | |||
Equity Compensation Plans Not Approved by Security Holders | | | | | — | | | | | | — | | | | | | — | | |
| | | Amount ($) | | |||
RSAs and RSUs(1) | | | | | 459,540 | | |
PSAs and PSUs vesting on December 31, 2020(2) | | | | | 1,168,830 | | |
12-month-vesting PSAs and PSUs(3) | | | | | 2,452,545 | | |
Vesting of stock options(4) | | | | | 316,476 | | |
| | Year Ended December 31, | | | Year Ended December | | ||||||||||||||||||||
| | 2020 | | 2019 | | | 31, 2021 | | 2020 | | ||||||||||||||||
| | (in thousands) | | | (in thousands) | | ||||||||||||||||||||
Audit Fees | | | $ | 1,615 | | | | $ | 1,777 | | | | | $ | 1,869 | | | | $ | 1,615 | | | ||||
Audit-Related Fees | | | | — | | | | | — | | | | | | — | | | | | — | | | ||||
Tax Fees | | | | 124 | | | | | 146 | | | | | | 134 | | | | | 124 | | | ||||
All Other Fees | | | | 2 | | | | | 2 | | | | | | 2 | | | | | 2 | | | ||||
Total Fees | | | $ | 1,741 | | | | $ | 1,925 | | | | | $ | 2,005 | | | | $ | 1,741 | | |